JonesTrading analyst Soumit Roy maintains $Editas Medicine (EDIT.US)$ with a buy rating, and maintains the target price at $13.
According to TipRanks data, the analyst has a success rate of 22.3% and a total average return of -21.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Editas Medicine (EDIT.US)$'s main analysts recently are as follows:
The assessment of Editas Medicine's Q3 performance was marked as incremental in the wake of the company's strategic update.
The primary discussion among investors regarding Editas Medicine centers on the assessment of the company's new strategy as either progressive or regressive. The belief is that the company's reni-cel for sickle cell disease and transfusion-dependent thalassemia represents a less risky asset with potential for monetization. Moreover, this asset may provide critical insights that could influence future strategies for their in vivo candidates.
The emphasis on in vivo HSPC editing is viewed as a strategic utilization of Editas Medicine's expertise and resources to generate value. Anticipation is building for the forthcoming in vivo pipeline update in Q1 2025, along with further details on reni-cel BD activity.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
